Evofem Biosciences, Inc. financial data

Symbol
EVFM on OTC
Industry
Pharmaceutical Preparations
Location
12400 High Bluff Drive, Suite 600, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Neothetics, Inc. (to 1/5/2018)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 11.9 % -29.7%
Quick Ratio 1.78 % -61.5%
Debt-to-equity -116 % +6.7%
Return On Equity 12.6 %
Return On Assets -55 % -117%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 113M shares +147%
Common Stock, Shares, Outstanding 113M shares +467%
Entity Public Float 900K USD -52.6%
Common Stock, Value, Issued 11K USD +450%
Weighted Average Number of Shares Outstanding, Basic 75.2M shares +1458%
Weighted Average Number of Shares Outstanding, Diluted 75.2M shares -92.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 100M USD +1470%
Revenue from Contract with Customer, Excluding Assessed Tax 19.4M USD +6.29%
Research and Development Expense 1.85M USD -37.2%
Selling and Marketing Expense 9.18M USD -21.3%
General and Administrative Expense 11.6M USD -22.6%
Costs and Expenses 27M USD -25%
Operating Income (Loss) -7.68M USD +57%
Nonoperating Income (Expense) -1.18M USD -102%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -8.86M USD -117%
Income Tax Expense (Benefit) -8K USD -173%
Net Income (Loss) Attributable to Parent -8.86M USD -117%
Earnings Per Share, Basic -0.12 USD/shares -101%
Earnings Per Share, Diluted -0.12 USD/shares -340%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 639K USD -76.9%
Accounts Receivable, after Allowance for Credit Loss, Current 9.83M USD +71.3%
Inventory, Net 1.58M USD -7.07%
Assets, Current 13.6M USD +47.8%
Property, Plant and Equipment, Net 458K USD -61.9%
Operating Lease, Right-of-Use Asset 89K USD -16%
Other Assets, Noncurrent 36K USD +2.86%
Assets 23.8M USD +125%
Accounts Payable, Current 16.2M USD -4.98%
Employee-related Liabilities, Current 3.49M USD +33.9%
Accrued Liabilities, Current 5.51M USD +30.3%
Contract with Customer, Liability, Current 4.5M USD
Liabilities, Current 80.4M USD +11%
Operating Lease, Liability, Noncurrent 10K USD -23.1%
Liabilities 90.3M USD +24.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.63M USD -210%
Retained Earnings (Accumulated Deficit) -898M USD -1.01%
Stockholders' Equity Attributable to Parent -71.3M USD -7.14%
Liabilities and Equity 23.8M USD +125%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 123K USD
Net Cash Provided by (Used in) Financing Activities 1.7M USD -88.8%
Net Cash Provided by (Used in) Investing Activities -14K USD -367%
Common Stock, Shares Authorized 3B shares 0%
Common Stock, Shares, Issued 113M shares +467%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 109K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 741K USD +27.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 500K USD
Deferred Tax Assets, Valuation Allowance 146M USD +1.13%
Deferred Tax Assets, Gross 146M USD +1.01%
Operating Lease, Liability 89K USD -11%
Depreciation 244K USD -95.1%
Payments to Acquire Property, Plant, and Equipment 14K USD +367%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -10.6M USD -508%
Lessee, Operating Lease, Liability, to be Paid 92K USD -19.3%
Property, Plant and Equipment, Gross 1.16M USD -51.5%
Operating Lease, Liability, Current 82K USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8K USD -87.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 84K USD +78.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -66.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5K USD -99.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.04M USD -0.26%
Operating Lease, Payments 64K USD -89.5%
Additional Paid in Capital 829M USD +0.73%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 301K USD
Share-based Payment Arrangement, Expense 847K USD -28.8%
Interest Expense 564K USD -0.18%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%